What IBD does

IBD Italian Biomedical Devices SRL (IBD Biomed) is an Italy-based private innovative SME (PMI Innovativa) founded in May 2014 in Bologna by physician Corrado Ghidini (CEO/CFO) and biomedical engineer Andrea Visotti (R&D Manager). The company designs and commercializes portable, low-cost medical devices built around a "Reverse Innovation" philosophy — products are engineered to be economically accessible while delivering hospital-grade efficacy. Its current portfolio consists of two Class IIa CE-certified platforms: Biorespira, a portable (3 kg) high-flow non-invasive ventilation (NIV) generator with closed-system architecture, integrated oxygen mixing (FiO2 21–100%), SpO2/PEEP monitoring and 10-inch touchscreen, originally developed in five weeks during COVID-19; and MyDial, a portable (18 kg) bicarbonate hemodialysis system built around a proprietary hydraulic-circuit manifold integrating sensors and actuators on a sub-A4 footprint, designed for home and emerging-market use with low-cost disposable kits.

The company monetizes primarily through direct B2B sales of hardware to hospitals and care facilities (approximately 600 Biorespira units sold by 2021 across named Italian public hospitals including Ospedale Maggiore Bologna, Sant'Orsola-Malpighi Polyclinic and Ospedale Sant'Eugenio Rome), supplemented by recurring revenue from MyDial's single-use disposable kits and non-dilutive grants (POR FESR, EU Horizon 2020 Seals of Excellence, SME internationalization grant). Go-to-market combines direct enterprise sales (medical and investor inquiry forms on the website), channel/distributor partnerships developed at Medica Düsseldorf and Arab Health Dubai, and an industrial-scale production and global distribution agreement with SECO S.p.A. enabling combined output of 80 non-invasive ventilators per day. Cumulative external funding exceeds €1 million from business angels, grants and a €20,000 COVID-era crowdfunding campaign, with an active new funding round underway. The team is small (8 named core members publicly; 11–50 employee band) and the company is currently building a 1,300 sqm operational headquarters in Forlì while executing international expansion (Egypt market launch for MyDial in June 2025; MENA distribution engagement via the MENA Hospital Projects Forum 2024 in Dubai).

Name

IBD

Legal name

IBD Italian Biomedical Devices SRL

Website

https://ibdbiomed.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

IBD Italian Biomedical Devices SRL is an Italian innovative SME that designs and commercializes portable, affordable Class IIa medical devices — the Biorespira NIV ventilator and the MyDial portable hemodialysis system — for hospitals, home-care patients, and emerging-market healthcare systems.

Ownership category

akta.pro rank

Product category

Medical Devices (Respiratory Ventilation and Hemodialysis Equipment)

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home) (HLAHAGAC)

akta.pro secondary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

Keywords

• Medical device manufacturing
• Portable hemodialysis systems
• Non-invasive ventilators
• Biomedical devices
• Home healthcare equipment

Headquarters

HQ city

Castiglione Delle Stiviere

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical device hardware sales (Biorespira and MyDial): One-time sale of medical devices; company reports approximately 600 Biorespira devices sold across hospitals including Ospedale Maggiore (Bologna), Sant'Orsola Malpighi Polyclinic (Bologna) and Ospedale Sant'Eugenio (Rome).
2. Disposable accessories for MyDial hemodialysis: Recurring revenue stream from customized, low-cost single-use disposable kits required for each MyDial treatment session; designed to be affordable while generating ongoing consumable revenue.
3. Non-dilutive grants and non-repayable public funding: Funding from sources including POR FESR (€100k non-repayable loan from Emilia-Romagna Region) and EU Horizon 2020 Seals of Excellence; complements business angel funding raised (€1M+ to date).
4. Crowdfunding campaign (#LetThemBreathe / GoFundMe): Successful crowdfunding campaign raised €20,000 specifically to support Biorespira development activities during COVID-19 response.

Pricing tiers

Go-to-market motion5 records

Distribution channels4 records

Marketing channels6 records

Core offering

IBD designs, develops and manufactures two CE-certified Class IIa medical devices: Biorespira, a portable high-flow non-invasive ventilation (NIV/CPAP/HFT) generator for sub-intensive, hospital, nursing-home and home respiratory care; and MyDial, a portable bicarbonate hemodialysis system with proprietary hydraulic manifold and low-cost disposable kits designed for home and emerging-market dialysis. Products are commercialized through direct sales to hospitals, international distributors and a strategic manufacturing partnership with SECO S.p.A.

Product overview

IBD Italian Biomedical Devices is an innovative SME that markets a two-product portfolio of medical devices applying the principles of Reverse Innovation to make quality healthcare affordable. Its offering is a focused dual-product line — not a unified platform with add-on modules — centered on the Biorespira lung ventilator (a portable high-flow NIV/CPAP generator for sub-intensive care, hospitals, nursing homes, and homes) and the MyDial portable hemodialysis system (a compact, low-cost bicarbonate dialysis device for home care and emerging markets). The two products share a common design philosophy (Reverse Innovation, clinical safety, international deployability) and were both developed internally and industrialized through strategic partnerships (notably with SECO S.p.A. for Biorespira). Together they target the respiratory and renal chronic-disease segments with the stated goal of "Life before dialysis. MyDial." and saving more lives through accessible NIV.

Differentiator

Problem solved

Functional benefit

Brands

• Biorespira: Lung ventilator (high flow generator with CPAP) for non-invasive pulmonary ventilation; supports chronic and acute patients in clinical, nursing-home and home settings.
• MyDial
• BioRespira

Products and services

• Biorespira Portable (3 kg) high-flow NIV/CPAP/HFT generator with integrated closed-system architecture, adjustable FiO2 21–100%, PEEP pressure sensor and integrated oximeter (SpO2, heart rate, respiratory rate); CE-certified Class IIa device for hospital sub-intensive care, nursing homes, emergency rooms and home oxygen-therapy use in adult autonomous-breathing patients.
• MyDial Portable (18 kg, 40x38x32 cm) bicarbonate hemodialysis system with integrated touch-screen interface, blood flow up to 500 ml/min, customized low-cost disposable kits and a proprietary hydraulic-circuit manifold; CE-certified for hospital use, designed to enable home dialysis, small-satellite-center use and emerging-market access.

Quantifiable outcome

• Approximately 600 Biorespira ventilators sold (2021) across Italian hospitals
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered flagship and supporting.

• SECO S.p.A.flagshipStrategic or Co-development PartnerLong-time IBD partner that brought mass-production, marketing, sales and global distribution for Biorespira. SECO's CEO Massimo Mauri stated: 'Partnering with IBD to bring BioRespira beyond early development and into production and worldwide distribution was an easy decision for SECO. The combination of SECO expertise with IBD innovation yields a powerful and vital solution to a worldwide crisis.' IBD BioMed and SECO together can produce 80 non-invasive ventilators per day.
• SECO Group (with FII Tech Growth managed by Italian Investment Fund SGR)flagshipStrategic or Co-development PartnerPartnership with SECO Group — a leading hi-tech company specialized in IT miniaturization, supported by FII Tech Growth (managed by Italian Investment Fund SGR) — for the industrialization of Biorespira. SECO Group provided high-quality production infrastructure.
• Test'Ing SrlsupportingTechnology or IntegrationEngineering/testing partner acknowledged by IBD alongside SECO spa and EOStech S.r.l. for Biorespira CE certification achievement.
• EOStech S.r.l.supportingTechnology or IntegrationTechnology partner acknowledged alongside SECO spa and Test'Ing Srl in achieving Biorespira CE certification for the European market.
• KIWA Cermet ItaliasupportingOthersNotified Body that performed testing, validation and CE certification of Biorespira as a Class IIa medical device under 93/42/CEE.
• Hospital of Desenzano del Garda (Dr. Nicola Petrucci, Chief of ICU)supportingImplementation/ SI/ Consulting PartnerClinical partner — Dr. Petrucci identified the need for high-flux NIV ventilators during the COVID-19 emergency and validated Biorespira clinically. The hospital was the first recipient of donated Biorespira units.
• Prof. Stefano Nava (S.Orsola-Malpighi Polyclinic, Bologna)supportingImplementation/ SI/ Consulting PartnerDirector of Pneumology and Respiratory Intensive Care at S.Orsola-Malpighi; clinical KOL cited in Biorespira publications and éTV interview supporting NIV adoption and Biorespira use in semi-intensive therapy.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• AWAK Technologies: Singapore-based developer of portable/wearable peritoneal dialysis (PD) technology. Adjacent peer to MyDial in the broader mission of dehospitalizing dialysis treatment and serving home-care chronic kidney disease patients, though using PD rather than hemodialysis.

Broad incumbents

• Mindray: Chinese global medtech with a wide patient-monitoring-and-ventilation portfolio (SV300, ePM) targeting hospitals worldwide. Overlaps with Biorespira in ICU/sub-intensive ventilation and increasingly in emerging markets where IBD is launching (Egypt, MENA).
• ResMed: Global leader in sleep and respiratory care with broad NIV/CPAP portfolio (Lumis, Stellar, AirCurve). Directly comparable to IBD's Biorespira in target therapy (non-invasive ventilation) and respiratory-care customer base, but operates at vastly larger scale across hospital and home-care channels.
• Philips Respironics: Major NIV/CPAP and hospital ventilation franchise (V60, Trilogy Evo) directly competing with Biorespira in sub-intensive and home NIV. Comparable end-user segments (hospitals, ICUs, home-care respiratory patients) and similar CE/FDA regulatory pathway, though operating at global incumbent scale.
• Dräger: German medical and safety technology company with a strong hospital ventilation portfolio (Savina, Evita, Oxylog). Directly comparable to Biorespira in NIV/CPAP hospital use cases and shares IBD's home-and-emergency multi-environment positioning, but at global incumbent scale with FDA and CE clearance.
• B. Braun Avitum: Major European dialysis equipment and services provider offering home hemodialysis solutions. Comparable to MyDial in portable/home dialysis targeting and in serving European hospital and satellite-center customers under MDR-compliant CE-marked products.
• Fresenius Medical Care (NxStage): Largest global dialysis services and products company, owner of the NxStage home hemodialysis system. Directly competes with MyDial in portable/home dialysis and dominates the same EU and US patient pools IBD targets, with vastly greater clinical data, reimbursement and field-service infrastructure.

Direct peers

• Hamilton Medical: Swiss manufacturer of intelligent ventilation solutions for ICUs and sub-intensive care (HAMILTON-C1, G5). Closely comparable to Biorespira in target clinical use case (sub-intensive/emergency NIV), customer profile (hospital ICUs and respiratory wards) and CE Class IIa regulatory positioning.
• Outset Medical: US-listed company behind the Tablo portable hemodialysis system — a near-direct analog to MyDial in the home/satellite dialysis use case. Targets the same patient transition from in-center to home hemodialysis that MyDial addresses, with a recurring consumable revenue model and FDA-cleared platform.
• Quanta Dialysis Technologies: UK-based developer of the SC+ portable hemodialysis system for home and clinic use. Direct peer to MyDial in compact portable dialysis hardware, low-cost disposable architecture, and the strategy of enabling hospital-grade dialysis outside traditional centers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=ztna1lt_LZE
• LinkedInlinkedin.com/company/ibd-biomed
• Facebookfacebook.com/IBDBioMed

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBD